EAU PCa 2018: Patient Selection for Prostate Biopsy

Milan, Italy (UroToday.com)  Dr. Joniau and Dr. Emberton gave an overview on the indications on which patients to refer for prostate biopsy.  There is an impressively high prevalence of prostate cancer in men in each decade, which can roughly amount to 30% in age 60-69, 40% in age 70-79, and 50% in US and European Caucasian men aged 80-89. This data has been shown in autopsy studies, as can be seen in figure 1, stratified by race as well.

EAU PCa 2018: Is There a Place for PET Scanning in the Primary Diagnosis of Prostate Cancer?

Milan, Italy (UroToday.com) Dr. Oyen gave a discussion on the role of PET imaging in the primary diagnosis of prostate cancer. There are currently many types of molecular imaging that can be used to image and diagnose prostate cancer. These include choline, F-18-FACBC (Fluciclovine), PSMA (with seven different subtypes), F-18-FDHT, FDG, diphosphonate bone scan, and Na-F-18. Figure 1 illustrates the diagnosis of prostate cancer metastases using some of these various PET/CT tracers.

EAU PCa 2018: Prostate Biopsy: Fusion, Systematic or Both?

Milan, Italy (UroToday.com) A summary on the use and the comparison of systematic standard biopsy with mpMRI targeted prostate biopsy was given by Dr. Everaerts.  The ideal biopsy strategy would detect all significant prostate cancer and minimize the detection (and consequent overtreatment) of insignificant prostate cancer. The European Association of Urology (EAU) guidelines state that mpMRI should be used only before repeat biopsy when clinical suspicion of prostate cancer persists despite negative biopsies. When the mpMRI discovers a lesion, this should undergo a targeted biopsy with systematic biopsies as well.

EAU PCa 2018: When to Use MRI in the Diagnosis of Prostate Cancer?

Milan, Italy (UroToday.com) Dr. Villeirs gave an update on the usage of MRI in the diagnosis of prostate cancer. He began his discussion on the scoring system of prostate MRI:  The Prostate Imaging Reporting and Data System (PIRADS), defining standards of high-quality clinical service for multi-parametric Magnetic Resonance Imaging (mpMRI), including image creation and reporting.
Page 3 of 3

Newsletter subscription

Free Daily and Weekly newsletters offered by content of interest

The fields of GU Oncology and Urology are rapidly advancing. Sign up today for articles, videos, conference highlights and abstracts from peer-review publications by disease and condition delivered to your inbox and read on the go.